北陆药业(300016) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was CNY 188.04 million, representing a year-over-year increase of 2.23% compared to CNY 183.93 million in the same period last year[4]. - Net profit attributable to shareholders decreased by 67.97% to CNY 12.58 million from CNY 39.26 million in the previous year[4]. - The net profit after deducting non-recurring gains and losses fell by 74.38% to CNY 8.61 million from CNY 33.60 million year-over-year[4]. - Total operating revenue for Q1 2023 was CNY 188,036,687.69, an increase of 2.4% compared to CNY 183,930,040.70 in Q1 2022[30]. - Net profit for Q1 2023 was CNY 10,184,088.91, a decrease of 70.7% from CNY 34,776,332.03 in Q1 2022[31]. - The company reported a gross profit margin of approximately 5.4% for Q1 2023, down from 19.5% in Q1 2022[30]. - The company's basic earnings per share for Q1 2023 was CNY 0.0256, down from CNY 0.0800 in Q1 2022[31]. Research and Development - The company reported a significant increase in R&D expenses, totaling CNY 17.04 million, which is a 128.07% increase compared to the previous year[10]. - R&D investment reached 17.04 million yuan in Q1 2023, a year-on-year increase of 128.07%[18]. - The company continues to develop products in the fields of contrast agents, endocrinology, cardiovascular, and digestive systems[18]. Cash Flow and Liquidity - Operating cash flow for the period was CNY 35.85 million, reflecting a 67.68% increase from CNY 21.38 million in the same quarter last year[10]. - The company’s cash flow from operating activities showed a significant decline, impacting liquidity[33]. - The net cash flow from operating activities increased to ¥35,846,735.41 from ¥21,378,261.26, representing a growth of approximately 67.9%[34]. - Cash inflow from operating activities totaled ¥225,116,862.35, slightly down from ¥228,618,017.48, a decrease of about 1.1%[34]. - Cash outflow from operating activities decreased to ¥189,270,126.94 from ¥207,239,756.22, a reduction of approximately 8.7%[34]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2.88 billion, up 2.21% from CNY 2.82 billion at the end of the previous year[6]. - Total assets amounted to CNY 2,877,714,818.93, an increase from CNY 2,815,514,459.14 year-over-year[27]. - Total liabilities increased to CNY 943,745,424.99, compared to CNY 892,274,093.48 in the previous year[27]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 28,755[13]. - The largest shareholder, Wang Daixue, holds 20.87% of shares, amounting to 102,664,727 shares, with 18,643,520 shares pledged[13]. Market Strategy - The company is actively expanding its market outside of centralized procurement, with ongoing efforts in provincial procurement[16]. - The company plans to focus on market expansion and new product development in the upcoming quarters to drive growth[26]. Cash Management - The company's cash and cash equivalents decreased by 14.12% to CNY 65.85 million compared to the beginning of the period[9]. - The company’s cash and cash equivalents at the end of Q1 2023 were 658,452,394.74 yuan, down from 766,734,641.15 yuan at the beginning of the year[23]. - The ending balance of cash and cash equivalents was ¥628,227,882.71, compared to ¥407,009,554.60 in the previous period, an increase of about 54.2%[36]. - The company received cash from borrowings amounting to ¥69,800,000.00, an increase from ¥57,276,000.00, representing a growth of approximately 22.1%[36]. - The company reported a cash inflow of ¥230,000,000.00 from other investment activities, a substantial increase from ¥10,000,000.00, marking a growth of approximately 2200%[34].